VYNE
VYNE Therapeutics Inc.
Biotechnology
Market Cap$29M
5Y Perf.-99.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
VYNE vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.61B
5Y Perf.-78.6%
VYNE vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VYNE | PRGO |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $29M | $1.61B |
| Revenue (TTM) | $570K | $4.18B |
| Net Income (TTM) | $-26M | $-1.82B |
| Gross Margin | 99.1% | 34.2% |
| Operating Margin | -52.2% | -4.1% |
| Forward P/E | — | 5.6x |
| Total Debt | $0.00 | $3.97B |
| Cash & Equiv. | $24M | $532M |
VYNE vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VYNE
PRGO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| VYNE Therapeutics I… (VYNE) | 100 | 0.4 | -99.6% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VYNE vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: VYNE and PRGO are tied at the top with 3 categories each — the right choice depends on your priorities. Perrigo Company plc is the stronger pick specifically for profitability and margin quality and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
VYNE
VYNE Therapeutics Inc.
The Income Pick
VYNE carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.74
- Rev growth 13.8%, EPS growth 34.0%, 3Y rev CAGR 6.1%
- Lower volatility, beta 0.74, current ratio 12.53x
Best for: income & stability and growth exposure
PRGO
Perrigo Company plc
The Long-Run Compounder
PRGO is the clearest fit if your priority is long-term compounding.
- -77.7% 10Y total return vs VYNE's -100.0%
- -43.5% margin vs VYNE's -46.5%
- 9.8% yield; 10-year raise streak; the other pay no meaningful dividend
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | VYNE | 13.8% revenue growth vs PRGO's -2.8% |
| Quality / Margins | PRGO | -43.5% margin vs VYNE's -46.5% |
| Stability / Safety | VYNE | Beta 0.74 vs PRGO's 1.18 |
| Dividends | PRGO | 9.8% yield; 10-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | VYNE | -50.8% vs PRGO's -51.2% |
| Efficiency (ROA) | PRGO | -19.8% ROA vs VYNE's -63.3%, ROIC 3.7% vs -124.0% |
VYNE vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
VYNE vs PRGO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRGOLAGGINGVYNE
VYNEVYNE Therapeutics Inc.
0leads
PRGOPerrigo Company plc
3leads
6 Total Categories
CATEGORYLEADERvs VYNEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
PRGO3/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRGO5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
PRGO4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — VYNE and PRGO each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 7330.5x VYNE's $570,000. Profitability is closely matched — net margins range from -43.5% (PRGO) to -46.5% (VYNE). On growth, VYNE holds the edge at +54.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VYNEVYNE Therapeutics… | PRGOPerrigo Company p… |
|---|---|---|
| RevenueTrailing 12 months | $570,000 | $4.2B |
| EBITDAEarnings before interest/tax | -$30M | $58M |
| Net IncomeAfter-tax profit | -$26M | -$1.8B |
| Free Cash FlowCash after capex | -$33M | $108M |
| Gross MarginGross profit ÷ Revenue | +99.1% | +34.2% |
| Operating MarginEBIT ÷ Revenue | -52.2% | -4.1% |
| Net MarginNet income ÷ Revenue | -46.5% | -43.5% |
| FCF MarginFCF ÷ Revenue | -58.1% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +54.8% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +57.1% | -56.4% |
Evenly matched — VYNE and PRGO each lead in 3 of 6 comparable metrics.
Valuation Metrics
PRGO leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | VYNEVYNE Therapeutics… | PRGOPerrigo Company p… |
|---|---|---|
| Market CapShares × price | $29M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $5M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.09x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.56x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 7.42x |
| Price / SalesMarket cap ÷ Revenue | 50.53x | 0.38x |
| Price / BookPrice ÷ Book value/share | 1.04x | 0.55x |
| Price / FCFMarket cap ÷ FCF | — | 11.12x |
PRGO leads this category, winning 3 of 3 comparable metrics.
Profitability & Efficiency
PRGO leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
PRGO delivers a -50.7% return on equity — every $100 of shareholder capital generates $-51 in annual profit, vs $-74 for VYNE. On the Piotroski fundamental quality scale (0–9), PRGO scores 4/9 vs VYNE's 2/9, reflecting mixed financial health.
| Metric | VYNEVYNE Therapeutics… | PRGOPerrigo Company p… |
|---|---|---|
| ROE (TTM)Return on equity | -74.1% | -50.7% |
| ROA (TTM)Return on assets | -63.3% | -19.8% |
| ROICReturn on invested capital | -124.0% | +3.7% |
| ROCEReturn on capital employed | -74.5% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | — | 1.35x |
| Net DebtTotal debt minus cash | -$24M | $3.4B |
| Cash & Equiv.Liquid assets | $24M | $532M |
| Total DebtShort + long-term debt | $0 | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | — | -7.20x |
PRGO leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
PRGO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRGO five years ago would be worth $3,986 today (with dividends reinvested), compared to $103 for VYNE. Over the past 12 months, VYNE leads with a -50.8% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors PRGO at -25.2% vs VYNE's -57.3% — a key indicator of consistent wealth creation.
| Metric | VYNEVYNE Therapeutics… | PRGOPerrigo Company p… |
|---|---|---|
| YTD ReturnYear-to-date | +16.1% | -13.5% |
| 1-Year ReturnPast 12 months | -50.8% | -51.2% |
| 3-Year ReturnCumulative with dividends | -92.2% | -58.1% |
| 5-Year ReturnCumulative with dividends | -99.0% | -60.1% |
| 10-Year ReturnCumulative with dividends | -100.0% | -77.7% |
| CAGR (3Y)Annualised 3-year return | -57.3% | -25.2% |
PRGO leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — VYNE and PRGO each lead in 1 of 2 comparable metrics.
Risk & Volatility
VYNE is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRGO currently trades 41.2% from its 52-week high vs VYNE's 34.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VYNEVYNE Therapeutics… | PRGOPerrigo Company p… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.74x | 1.18x |
| 52-Week HighHighest price in past year | $1.96 | $28.44 |
| 52-Week LowLowest price in past year | $0.28 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +34.4% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 68.7 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 192K | 3.4M |
Evenly matched — VYNE and PRGO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | VYNEVYNE Therapeutics… | PRGOPerrigo Company p… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $20.00 |
| # AnalystsCovering analysts | — | 36 |
| Dividend YieldAnnual dividend ÷ price | — | +9.8% |
| Dividend StreakConsecutive years of raises | — | 10 |
| Dividend / ShareAnnual DPS | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRGO leads in 3 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 2 categories are tied.
Best OverallPerrigo Company plc (PRGO)Leads 3 of 6 categories
Loading custom metrics...
VYNE vs PRGO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is VYNE or PRGO a better buy right now?
For growth investors, VYNE Therapeutics Inc.
(VYNE) is the stronger pick with 13. 8% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Analysts rate Perrigo Company plc (PRGO) a "Hold" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VYNE or PRGO?
Over the past 5 years, Perrigo Company plc (PRGO) delivered a total return of -60.
1%, compared to -99. 0% for VYNE Therapeutics Inc. (VYNE). Over 10 years, the gap is even starker: PRGO returned -77. 7% versus VYNE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VYNE or PRGO?
By beta (market sensitivity over 5 years), VYNE Therapeutics Inc.
(VYNE) is the lower-risk stock at 0. 74β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 60% more volatile than VYNE relative to the S&P 500.
04Which is growing faster — VYNE or PRGO?
By revenue growth (latest reported year), VYNE Therapeutics Inc.
(VYNE) is pulling ahead at 13. 8% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: VYNE Therapeutics Inc. grew EPS 34. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, VYNE leads at 6. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VYNE or PRGO?
Perrigo Company plc (PRGO) is the more profitable company, earning -33.
5% net margin versus -46. 5% for VYNE Therapeutics Inc. — meaning it keeps -33. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -52. 2% for VYNE. At the gross margin level — before operating expenses — VYNE leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — VYNE or PRGO?
In this comparison, PRGO (9.
8% yield) pays a dividend. VYNE does not pay a meaningful dividend and should not be held primarily for income.
07Is VYNE or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
18), 9. 8% yield). Both have compounded well over 10 years (PRGO: -77. 7%, VYNE: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between VYNE and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: VYNE is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while VYNE does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(VYNE: 54.8% · PRGO: -7.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.